Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers

BMC Dermatology

Volumn 15, Issue 1, 2015, Pages

  Reisman, Scott A ^a   Goldsberry, Angela R ^a   Lee, Chun Yue I ^a   O'Grady, Megan L ^a   Proksch, Joel W ^a   Ward, Keith W ^a   Meyer, Colin J ^a  

^a Reata Pharmaceuticals Inc   (United States)

Author keywords

Cancer supportive care; Nrf2; Radiation dermatitis; RTA 408 lotion

Indexed keywords

ALANINE AMINOTRANSFERASE; DERMATOLOGICAL AGENT; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RTA 408; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; N-(11-CYANO-2,2,6A,6B,9,9,12A-HEPTMETHYL-10,14-DIOXO-1,3,4,5,6A,6B,7,8,8A,9,10,12A,14,14A,14B-HEXADECAHYDRO-2H-PICEN-4A-YL)-2-2-DIFLUOROPROPIONAMIDE; NQO1 PROTEIN, HUMAN; SKIN CREAM; TRITERPENE;

ADULT; ADVERSE OUTCOME; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; ARTICLE; CLINICAL STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; EXPLANT; FEASIBILITY STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; KERATINOCYTE; LIMIT OF QUANTITATION; LOTION; MALE; MODIFIED DRAIZE SCORE; NORMAL HUMAN; NQO1 GENE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN BIOPSY; SKIN SURFACE; UPREGULATION; ADOLESCENT; AGED; CELL CULTURE TECHNIQUE; CLINICAL TRIAL; CUTANEOUS DRUG ADMINISTRATION; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; SKIN; TISSUE CULTURE TECHNIQUE; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; CELL CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; HUMANS; KERATINOCYTES; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; SKIN; SKIN CREAM; TISSUE CULTURE TECHNIQUES; TRITERPENES; YOUNG ADULT;

EID: 84937026323     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/s12895-015-0029-7     Document Type: Article

References (16)

1. Lisk C, McCord J, Bose S, Sullivan T, Loomis Z, Nozik-Grayck E, et al. Nrf2 activation: a potential strategy for the prevention of acute mountain sickness. Free Radic Biol Med. 2013;63:264-73. doi: 10.1016/j.freeradbiomed.2013.05.024 .
2. Ludtmann MH, Angelova PR, Zhang Y, Abramov AY, Dinkova-Kostova AT. Nrf2 affects the efficiency of mitochondrial fatty acid oxidation. Biochem J. 2014;457(3):415-24. doi: 10.1042/BJ20130863 .
3. Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci. 2013;34(6):340-6. doi: 10.1016/j.tips.2013.04.005 .
4. Pedruzzi LM, Stockler-Pinto MB, Leite Jr M, Mafra D. Nrf2-keap1 system versus NF-kappaB: the good and the evil in chronic kidney disease? Biochimie. 2012;94(12):2461-6. doi: 10.1016/j.biochi.2012.07.015 .
5. Takaya K, Suzuki T, Motohashi H, Onodera K, Satomi S, Kensler TW, et al. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med. 2012;53(4):817-27. doi: 10.1016/j.freeradbiomed.2012.06.023 .
6. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod. 2011;74(3):537-45. doi: 10.1021/np100826q .
7. Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev. 2012;64(4):972-1003. doi: 10.1124/pr.111.004846 .
8. Cleasby A, Yon J, Day PJ, Richardson C, Tickle IJ, Williams PA, et al. Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO. PLoS One. 2014;9(6), e98896. doi: 10.1371/journal.pone.0098896 .
9. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Ward KW. Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin. Arch Dermatol Res. 2014;306(5):447-54. doi: 10.1007/s00403-013-1433-7 .
10. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW. Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis. Radiat Res. 2014;181(5):512-20. doi: 10.1667/RR13578.1 .
11. Reisman SA, Ward KW, Klaassen CD, Meyer CJ. CDDO-9,11-dihydro-trifluoroethyl amide (CDDO-dhTFEA) induces hepatic cytoprotective genes and increases bile flow in rats. Xenobiotica. 2013;43(7):571-8. doi: 10.3109/00498254.2012.750022 .
12. Reisman SA, Yeager RL, Yamamoto M, Klaassen CD. Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. Toxicol Sci. 2009;108(1):35-47. doi: 10.1093/toxsci/kfn267 .
13. Bito T, Nishigori C. Impact of reactive oxygen species on keratinocyte signaling pathways. J Dermatol Sci. 2012;68(1):3-8. doi: 10.1016/j.jdermsci.2012.06.006 .
14. Nakamura M, Rikimaru T, Yano T, Moore KG, Pula PJ, Schofield BH, et al. Full-thickness human skin explants for testing the toxicity of topically applied chemicals. J Invest Dermatol. 1990;95(3):325-32.
15. El-Ashmawy M, Delgado O, Cardentey A, Wright WE, Shay JW. CDDO-Me protects normal lung and breast epithelial cells but not cancer cells from radiation. PLoS One. 2014;9(12), e115600. doi: 10.1371/journal.pone.0115600 .
16. Alexeev V, Lash E, Aguillard A, Corsini L, Bitterman A, Ward K, et al. Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound. Mol Cancer Ther. 2014;13(12):2968-77. doi: 10.1158/1535-7163.MCT-14-0354 .